Assessing the Effects of ELO Water on Diabetic Foot Ulcers
A Pilot Study to Assess the Effects of Oxygen-enriched Water (ELO Water) on Wound Healing for Diabetic Foot Ulcers
1 other identifier
interventional
16
1 country
1
Brief Summary
This pilot study examined the effects of ELO water, a commercially-available oxygen-enriched drinking water, on wound healing in patients with diabetic foot ulcers over 12 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2017
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 19, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2021
CompletedFirst Submitted
Initial submission to the registry
June 4, 2023
CompletedFirst Posted
Study publicly available on registry
June 18, 2023
CompletedJune 18, 2023
June 1, 2023
2.2 years
June 4, 2023
June 16, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Reduction in wound area
Absolute and percentage reduction in wound area
12 weeks
Secondary Outcomes (1)
Complete wound closure
12 weeks
Study Arms (1)
Drinking ELO water
EXPERIMENTALDrinking 1.5 litres of ELO water daily
Interventions
Eligibility Criteria
You may qualify if:
- type 2 diabetes and haemoglobin A1c (HbA1c) at screening of 7.0-10.0% on oral glucose-lowering medication and/or insulin at a stable dose for the last three months
You may not qualify if:
- pregnant or lactating
- conditions which would independently worsen ulcer healing such as severe peripheral vascular disease or varicose veins
- immunosuppressive therapy
- comorbidities necessitating fluid restriction such as renal, liver or cardiac failure.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Changi General Hospitallead
- ELO Water Pte. Ltd.collaborator
Study Sites (1)
Joan Khoo
Singapore, 529889, Singapore
Related Publications (3)
Schreml S, Szeimies RM, Prantl L, Karrer S, Landthaler M, Babilas P. Oxygen in acute and chronic wound healing. Br J Dermatol. 2010 Aug;163(2):257-68. doi: 10.1111/j.1365-2133.2010.09804.x. Epub 2010 Apr 15.
PMID: 20394633RESULTSun XK, Li R, Yang XL, Yuan L. Efficacy and safety of topical oxygen therapy for diabetic foot ulcers: An updated systematic review and meta-analysis. Int Wound J. 2022 Dec;19(8):2200-2209. doi: 10.1111/iwj.13830. Epub 2022 May 5.
PMID: 35510518RESULTKhoo J, Hagemeyer CE, Henstridge DC, Kumble S, Wang TY, Xu R, Gani L, King T, Soh SB, Puar T, Au V, Tan E, Tay TL, Kam C, Teo EK. Effects of water stably-enriched with oxygen as a novel method of tissue oxygenation on mitochondrial function, and as adjuvant therapy for type 2 diabetes in a randomized placebo-controlled trial. PLoS One. 2021 Jul 14;16(7):e0254619. doi: 10.1371/journal.pone.0254619. eCollection 2021.
PMID: 34260650RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joan Khoo
Changi General Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 4, 2023
First Posted
June 18, 2023
Study Start
September 19, 2017
Primary Completion
November 30, 2019
Study Completion
June 30, 2021
Last Updated
June 18, 2023
Record last verified: 2023-06
Data Sharing
- IPD Sharing
- Will not share